Your Health, We Care
Concomitant use with strong CYP3A inhibitors may increase dasatinib concentrations. Increased dasatinib concentrations may raise the risk of toxicity. Avoid concurrent use of strong CYP3A4 inhibitors. If concurrent use of strong CYP3A4 inhibitors cannot be avoided, consider reducing the dasatinib dose.
Concomitant use of dasatinib with strong CYP3A inducers may decrease dasatinib concentrations. Decreased dasatinib concentrations may reduce efficacy. Consider using alternative drugs with less enzyme-inducing potential. If concurrent use of strong CYP3A4 inducers cannot be avoided, consider increasing the dasatinib dose.
Concomitant use of dasatinib with acid-reducing agents may decrease dasatinib concentrations. Decreased dasatinib concentrations may reduce efficacy.
Do not administer H2-receptor antagonists or proton pump inhibitors concomitantly with dasatinib. Consider using antacids instead of H2-receptor antagonists or proton pump inhibitors. Administer antacids at least 2 hours before or at least 2 hours after dasatinib administration. Avoid concurrent administration of dasatinib with antacids.
FDA，2024.07
